Genzyme, the US biotechnology company, has a remarkably broad product
base in contrast to similar corporations which have more focused portf
olios. In biotechnology, a company's value is based largely upon its p
atent portfolio. In the case of Genzyme, the Company's leading product
Ceredase (recombinant glucocerebrosidase), is manufactured under lice
nce. Substantial income streams are produced from the manufacture of p
harmaceuticals and diagnostic reagents. Of particular note are Genzyme
's tissue repair products which combine membrane and recombinant DNA t
echnologies.